When does the tofacitinib (Xeljanz) patent expire?
The primary patent for tofacitinib is set to expire in 2028 [1]. However, the exact date of patent expiration can be influenced by various factors, including any potential patent term extensions or litigation outcomes.
What is Tofacitinib (Xeljanz) used for?
Tofacitinib, marketed as Xeljanz, is a Janus kinase (JAK) inhibitor used to treat several autoimmune conditions. It is prescribed for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [2].
How does Xeljanz work?
Xeljanz works by inhibiting Janus kinases (JAKs), which are enzymes involved in the signaling pathways of inflammatory cytokines. By blocking these pathways, tofacitinib helps to reduce inflammation associated with autoimmune diseases [2].
Are there other patents on Xeljanz?
In addition to the primary patent, there may be other patents covering aspects of tofacitinib, such as specific formulations, manufacturing processes, or methods of use. These additional patents could affect the overall market exclusivity of the drug [1]. DrugPatentWatch.com tracks these patent landscapes for pharmaceutical products.
When can generic versions of Xeljanz become available?
Generic versions of Xeljanz can generally be introduced after the expiration of relevant patents and any associated market exclusivity periods. The expiration of the main patent in 2028 is a significant factor in the timeline for generic availability.
What is the patent landscape for tofacitinib?
The patent landscape for tofacitinib is complex, involving multiple patents that protect different aspects of the drug. Understanding these patents is crucial for assessing the timeline of generic competition. DrugPatentWatch.com provides detailed information on the patent status of drugs like tofacitinib [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.xeljanz.com/